Home › Ischemic Stroke › NCT07404852
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct 2
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients who present with acute ischemic strokes due to large vessel occlusions Exclusion Criteria: * \<18 years old * patients with presumed chronic large vessel occlusions * NIHSS\<6 * pre-morbid modified Rankin score (mRS) \>2 * unable to initiate treatment under 24 hours from symptom discovery * Chronic or acute infection, Recent surgery, active immune disease * life expectancy \<3 months * patients' undergoing active cancer or immunosuppressive/modulating therapy * patients with sustained bradycardia on arrival with a heart rate \<50 beats per minute.
About the study
This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory and brain injury laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.
What is being tested
- transcutaneous auricular vagal nerve stimulation (device)
- Sham transcutaneous vagal nerve stimulation (device)
Sponsor: Washington University School of Medicine · Participants: 65 · Started: Feb 23, 2026
Contact the study team
- Angela Birke, MS · Phone: (314) 362-5291
- Osvaldo Laurido-Soto, MD · Phone: 314-273-3294
Official record on ClinicalTrials.gov — NCT07404852
Locations in the U.S.
| Missouri | Barnes-Jewish Hospital, St Louis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.